Effect of chronic l-DOPA treatment on 5-HT1A receptors in parkinsonian monkey brain

Neurochemistry International

Volumn 61, Issue 7, 2012, Pages 1160-1171

  Riahi, Golnasim ^a,b,d   Morissette, Marc ^b   Lévesque, Daniel ^c   Rouillard, Claude ^a,b   Samadi, Pershia ^a,b   Parent, Martin ^a,d   Paolo, Thérèse Di ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

8 OH DPAT; Basal ganglia; l DOPA induced dyskinesia; Parkinson's disease; Primate; Serotonin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL) 2 THIAZOLYL]BENZENESULFONAMIDE; 5 HYDROXYINDOLEACETIC ACID; DOCOSAHEXAENOIC ACID; DOPAMINE; KYNURENINE 3 MONOOXYGENASE; LEVODOPA; NALTREXONE; OXYGENASE INHIBITOR; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CINGULATE GYRUS; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG RECEPTOR BINDING; DYSKINESIA; FEMALE; HAPLORHINI; LONG TERM CARE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUPERIOR FRONTAL GYRUS;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; FEMALE; LEVODOPA; MACACA FASCICULARIS; PARKINSONIAN DISORDERS; RECEPTORS, SEROTONIN, 5-HT1;

ANIMALIA; PARKINSONIA; PRIMATES;

EID: 84870053418     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.08.009     Document Type: Article

References (67)

1. Y. Agid, P. Cervera, E. Hirsch, F. Javoy-Agid, S. Lehericy, R. Raisman, and M. Ruberg Biochemistry of Parkinson's disease 28 years later: a critical review Mov. Disord. 4 Suppl. 1 1989 S126 S144
2. T. Antonelli, K. Fuxe, M.C. Tomasini, G.D. Bartoszyk, C.A. Seyfried, S. Tanganelli, and L. Ferraro Effects of sarizotan on the corticostriatal glutamate pathways Synapse 58 2005 193 199
3. W. Bara-Jimenez, F. Bibbiani, M.J. Morris, T. Dimitrova, A. Sherzai, M.M. Mouradian, and T.N. Chase Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease Mov. Disord. 20 2005 932 936
4. N.M. Barnes, and T. Sharp A review of central 5-HT receptors and their function Neuropharmacology 38 1999 1083 1152
5. B. Bert, H. Fink, H. Hortnagl, R.W. Veh, B. Davies, F. Theuring, and H. Kusserow Mice over-expressing the 5-HT(1A) receptor in cortex and dentate gyrus display exaggerated locomotor and hypothermic response to 8-OH-DPAT Behav. Brain Res. 167 2006 328 341
6. C. Bédard, M.J. Wallman, E. Pourcher, P.V. Gould, A. Parent, and M. Parent Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea Parkinsonism Relat. Disord. 17 2011 593 598
7. R.J. Blanchard, J.K. Shepherd, J. Armstrong, S.F. Tsuda, and D.C. Blanchard An ethopharmacological analysis of the behavioral effects of 8-OH-DPAT Psychopharmacology 112 1993 55 63
8. R.J. Carey, G. Depalma, E. Damianopoulos, C.P. Muller, and J.P. Huston The 5-HT1A receptor and behavioral stimulation in the rat: effects of 8-OHDPAT on spontaneous and cocaine-induced behavior Psychopharmacology 177 2004 46 54
9. M. Carta, T. Carlsson, D. Kirik, and A. Bjorklund Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats Brain 130 2007 1819 1833
10. R. Cash, R. Raisman, A. Ploska, and Y. Agid High and low affinity [3H]imipramine binding sites in control and Parkinsonian brains Eur. J. Pharmacol. 117 1985 71 80
11. M.A. Cenci, and H.S. Lindgren Advances in understanding l-DOPA-induced dyskinesia Curr. Opin. Neurobiol. 17 2007 665 671
12. G. Chinaglia, B. Landwehrmeyer, A. Probst, and J.M. Palacios Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram Neuroscience 54 1993 691 699
13. T. Di Paolo, P. Bedard, M. Daigle, and R. Boucher Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys Brain Res. 379 2 1986 286 293
14. K.B. Dupre, K.L. Eskow, C.J. Barnum, and C. Bishop Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat Neuropharmacology 55 2008 1321 1328
15. K.B. Dupre, K.L. Eskow, A. Steiniger, A. Klioueva, G.E. Negron, L. Lormand, J.Y. Park, and C. Bishop Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat Psychopharmacology 199 2008 99 108
16. K.B. Dupre, C.Y. Ostock, K.L. Eskow Jaunarajs, T. Button, L.M. Savage, W. Wolf, and C. Bishop Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats Exp. Neurol. 229 2011 288 299
17. K.L. Eskow, K.B. Dupre, C.J. Barnum, S.O. Dickinson, J.Y. Park, and C. Bishop The role of the dorsal raphe nucleus in the development, expression, and treatment of l-DOPA-induced dyskinesia in hemiparkinsonian rats Synapse 63 2009 610 620
18. S.H. Fox, R. Chuang, and J.M. Brotchie Serotonin and Parkinson's disease: on movement, mood, and madness Mov. Disord. 24 2009 1255 1266
19. P.T. Francis, M.N. Pangalos, R.C. Pearson, D.N. Middlemiss, G.C. Stratmann, and D.M. Bowen 5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin J. Pharmacol. Exp. Ther. 261 1992 1273 1281
20. D. Frechilla, A. Cobreros, L. Saldise, R. Moratalla, R. Insausti, M. Luquin, and J. Del Rio Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys Synapse 39 2001 288 296
21. F.K. Goodwin, H.K. Brodie, D.L. Murphy, and W.E. Bunney Jr. Administration of a peripheral decarboxylase inhibitor with l-DOPA to depressed patients Lancet 1 1970 908 911
22. L. Grégoire, A. Rassoulpour, P. Guidetti, P. Samadi, P.J. Bédard, E. Izzo, R. Schwarcz, and T. Di Paolo Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys Behav. Brain Res. 186 2008 161 167
23. L. Grégoire, P. Samadi, J. Graham, P.J. Bédard, G.D. Bartoszyk, and T. Di Paolo Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys Parkinsonism Relat. Disord. 15 2009 445 452
24. M. Guttman, I. Boileau, J. Warsh, J.A. Saint-Cyr, N. Ginovart, T. McCluskey, S. Houle, A. Wilson, E. Mundo, P. Rusjan, J. Meyer, and S.J. Kish Brain serotonin transporter binding in non-depressed patients with Parkinson's disease Eur. J. Neurol. 14 2007 523 528
25. M. Hajos, E. Hajos-Korcsok, and T. Sharp Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat Br. J. Pharmacol. 126 1999 1741 1750
26. P. Huot, and J.M. Brotchie 5-HT(1A) receptor stimulation and l-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms Exp. Neurol. 231 2011 195 198
27. P. Huot, S.H. Fox, A. Newman-Tancredi, and J.M. Brotchie Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? J. Pharmacol. Exp. Ther. 339 2011 2 8
28. P. Huot, T.H. Johnston, J.B. Koprich, L. Winkelmolen, S.H. Fox, and J.M. Brotchie Regulation of cortical and striatal 5-HT(1A) receptors in the MPTP-lesioned macaque Neurobiol. Aging 33 207 2012 e9 e19
29. P. Huot, T.H. Johnston, N.P. Visanji, T. Darr, D. Pires, L.N. Hazrati, J.M. Brotchie, and S.H. Fox Increased levels of 5-HT(1A) receptor binding in ventral visual pathways in Parkinson's disease Mov. Disord. 27 2012 735 742
30. M.M. Iravani, K. Tayarani-Binazir, W.B. Chu, M.J. Jackson, and P. Jenner In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability J. Pharmacol. Exp. Ther. 319 2006 1225 1234
31. K. Kannari, H. Yamato, H. Shen, M. Tomiyama, T. Suda, and M. Matsunaga Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation J. Neurochem. 76 2001 1346 1353
32. K. Kannari, K. Kurahashi, M. Tomiyama, T. Maeda, A. Arai, M. Baba, T. Suda, and M. Matsunaga Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease No To Shinkei 54 2002 133 137
33. L. Kerenyi, G.A. Ricaurte, D.J. Schretlen, U. McCann, J. Varga, W.B. Mathews, H.T. Ravert, R.F. Dannals, J. Hilton, D.F. Wong, and Z. Szabo Positron emission tomography of striatal serotonin transporters in Parkinson disease Arch. Neurol. 60 2003 1223 1229
34. H.K. Kia, M.C. Miquel, M.J. Brisorgueil, G. Daval, M. Riad, S. El Mestikawy, M. Hamon, and D. Verge Immunocytochemical localization of serotonin1A receptors in the rat central nervous system J. Comp. Neurol. 365 1996 289 305
35. S.E. Kim, J.Y. Choi, Y.S. Choe, Y. Choi, and W.Y. Lee Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-β-CIT SPECT J. Nucl. Med. 44 2003 870 876
36. S.J. Kish, J. Tong, O. Hornykiewicz, A. Rajput, L.J. Chang, M. Guttman, and Y. Furukawa Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease Brain 131 2008 120 131
37. F. Lejeune, A. Newman-Tancredi, V. Audinot, and M.J. Millan Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats J. Pharmacol. Exp. Ther. 280 1997 1241 1249
38. Z. Li, J. Ichikawa, J. Dai, and H.Y. Meltzer Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain Eur. J. Pharmacol. 493 2004 75 83
39. H.S. Lindgren, D.R. Andersson, S. Lagerkvist, H. Nissbrandt, and M.A. Cenci l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J. Neurochem. 112 2010 1465 1476
40. S. Mahmoudi, P. Samadi, F. Gilbert, B. Ouattara, M. Morissette, L. Gregoire, C. Rouillard, T. Di Paolo, and D. Levesque Nur77 mRNA levels and l-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid Neurobiol. Dis. 36 2009 213 222
41. R.F. Martin, and D.M. Bowden Primate Brain Maps: Structure of the Macaque Brain 2000 Elsevier Science Amsterdam, The Netherlands pp. 1-60
42. F. Mauler, T. Fahrig, E. Horvath, and R. Jork Inhibition of evoked glutamate release by the neuroprotective 5-HT(1A) receptor agonist BAY × 3702 in vitro and in vivo Brain Res. 888 2001 150 157
43. R.K. McNamara, J. Able, Y. Liu, R. Jandacek, T. Rider, P. Tso, and J.W. Lipton Omega-3 fatty acid deficiency during perinatal development increases serotonin turnover in the prefrontal cortex and decreases midbrain tryptophan hydroxylase-2 expression in adult female rats: dissociation from estrogenic effects J. Psychiatr. Res. 43 2009 656 663
44. L. Mignon, and W.A. Wolf Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease Psychopharmacology 192 2007 49 59
45. J. Mo, H. Zhang, L.P. Yu, P.H. Sun, G.Z. Jin, and X. Zhen l-stepholidine reduced l-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease Neurobiol. Aging 31 2010 926 936
46. M. Moller, A. Rodell, and A. Gjedde Parametric mapping of 5HT1A receptor sites in the human brain with the Hypotime method: theory and normal values J. Nucl. Med. 50 2009 1229 1236
47. D. Morgan, and M.J. Picker Discriminative stimulus effects of the 5HT1A agonist 8-OH-DPAT: attenuation by mu but not by kappa opioids Psychopharmacology 122 1995 336 345
48. A. Munoz, Q. Li, F. Gardoni, E. Marcello, C. Qin, T. Carlsson, D. Kirik, M. Di Luca, A. Bjorklund, E. Bezard, and M. Carta Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia Brain 131 2008 3380 3394
49. S. Navailles, A. Benazzouz, B. Bioulac, C. Gross, and P. De Deurwaerdere High-frequency stimulation of the subthalamic nucleus and l-3,4- dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease J. Neurosci. 30 2010 2356 2364
50. C.W. Olanow, R.L. Watts, and W.C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines Neurology 56 2001 S1 S88
51. C.Y. Ostock, K.B. Dupre, K.L. Jaunarajs, H. Walters, J. George, D. Krolewski, P.D. Walker, and C. Bishop Role of the primary motor cortex in l-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation Neuropharmacology 61 2011 753 760
52. B. Ouattara, F. Gasparini, M. Morissette, L. Gregoire, P. Samadi, B. Gomez-Mancilla, and T. Di Paolo Effect of l-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys J. Neurochem. 113 2010 715 724
53. A. Parent, and L.N. Hazrati Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop Brain Res. Brain Res. Rev. 20 1995 91 127
54. M. Pompeiano, J.M. Palacios, and G. Mengod Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding J. Neurosci. 12 1992 440 453
55. R. Raisman, R. Cash, and Y. Agid Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen Neurology 36 1986 556 560
56. G. Riahi, M. Morissette, M. Parent, and T. Di Paolo Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias Eur. J. Neurosci. 33 2011 1823 1831
57. U.K. Rinne, V. Koskinen, and P. Lonnberg Neurotransmitter receptors in the parkinsonian brain U.K. Rinne, M. Klinger, G. Stamm, Parkinson's Disease: Current Progress, Problems and Management 1980 Elsevier North Holland, Amsterdam 93 107
58. F. Roselli, N.M. Pisciotta, M. Pennelli, M.S. Aniello, A. Gigante, M.F. De Caro, E. Ferrannini, B. Tartaglione, A. Niccoli-Asabella, G. Defazio, P. Livrea, and G. Rubini Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study Mov. Disord. 25 2010 1853 1859
59. D. Rylander, M. Parent, S.S. O'Sullivan, S. Dovero, A.J. Lees, E. Bezard, L. Descarries, and M.A. Cenci Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia Ann. Neurol. 68 2010 619 628
60. N. Saigal, R. Pichika, B. Easwaramoorthy, D. Collins, B.T. Christian, B. Shi, T.K. Narayanan, S.G. Potkin, and J. Mukherjee Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate J. Nucl. Med. 47 2006 1697 1706
61. P. Samadi, L. Grégoire, A. Hadj Tahar, T. Di Paolo, C. Rouillard, and P.J. Bédard Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naive parkinsonian monkeys Neuropharmacology 49 2005 165 173
62. P. Samadi, L. Grégoire, C. Rouillard, P.J. Bédard, T. Di Paolo, and D. Levesque Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys Ann. Neurol. 59 2006 282 288
63. B. Scatton, F. Javoy-Agid, L. Rouquier, B. Dubois, and Y. Agid Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease Brain Res. 275 1983 321 328
64. C.A. Stockmeier, L.A. Shapiro, J.W. Haycock, P.A. Thompson, and M.T. Lowy Quantitative subregional distribution of serotonin1A receptors and serotonin transporters in the human dorsal raphe Brain Res. 727 1996 1 12
65. M.K. Tamim, P. Samadi, M. Morissette, L. Gregoire, B. Ouattara, D. Levesque, C. Rouillard, and T. Di Paolo Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides Neuropharmacology 58 2010 286 296
66. J.L. Wang, S. Oya, A.K. Parhi, B.P. Lieberman, K. Ploessl, C. Hou, and H.F. Kung Comparison of the SERT-selective [18F]FPBM and VMAT2- selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease Nucl. Med. Biol. 37 2010 479 486
67. M. Wood, M. Chaubey, P. Atkinson, and D.R. Thomas Antagonist activity of meta-chlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT(7) receptor Eur. J. Pharmacol. 396 2000 1 8